about
Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repairTreatment of Breast and Prostate Cancer by Hypofractionated Radiotherapy: Potential Risks and BenefitsSequence variants at the TERT-CLPTM1L locus associate with many cancer typesDNA repair gene XRCC1 polymorphisms and bladder cancer risk.Analysis of variants in DNA damage signalling genes in bladder cancerLack of correlation between residual radiation-induced DNA damage, in keratinocytes assayed directly from skin, and late radiotherapy reactions in breast cancer patients.Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden.In vitro functional effects of XPC gene rare variants from bladder cancer patients.Functional assays to determine the significance of two common XPC 3'UTR variants found in bladder cancer patients.A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer.MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer.European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene.The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes.Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer.Sequence variant on 8q24 confers susceptibility to urinary bladder cancer.The polyAT, intronic IVS11-6 and Lys939Gln XPC polymorphisms are not associated with transitional cell carcinoma of the bladderFibroblast radiosensitivity measured using the comet DNA-damage assay correlates with clonogenic survival parametersIdentification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry.Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer.Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer.Common predisposition alleles for moderately common cancers: bladder cancer.Can γH2AX be used to personalise cancer treatment?Words of wisdom. Re: Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.Biomarkers of Tumour Radiosensitivity and Predicting Benefit from Radiotherapy.Post-transcriptional regulation of MRE11 expression in muscle-invasive bladder tumoursCrowdsourcing for translational research: analysis of biomarker expression using cancer microarrays.Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression.Imatinib radiosensitizes bladder cancer by targeting homologous recombination.Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity.Papillary and muscle invasive bladder tumors with distinct genomic stability profiles have different DNA repair fidelity and KU DNA-binding activities.DNA double strand break repair in human bladder cancer is error prone and involves microhomology-associated end-joining.Training to treat cancer: future developments.Army Cardiac Unit -- cardiac catheter patients, 1991--a review.Radiotherapy for node positive penile cancer: experience of the Leeds teaching hospitals.Relapse of intracranial germinoma 23 years postirradiation in a patient given growth hormone replacement.Survival and late effects in medulloblastoma patients treated with craniospinal irradiation under three years old.Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer.Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center.Comprehensive analysis of 22 XPC polymorphisms and bladder cancer risk.
P50
Q26863429-BBB68DC7-DBAE-46EE-8751-BCFEB8C807A4Q26998991-038AA42D-9A09-4AE3-8661-8F41C785A3BBQ29614935-DF6E1B42-F819-4B1A-98EB-321E9F545794Q30361009-215857F5-CDAF-4663-895A-BB5EB9CE6C0CQ33353037-DCE71A1D-CC83-4538-BDDF-8470ED8F1BFDQ33541467-AE46F402-D2F9-403B-B6F8-2E37D7DF3258Q33568623-5327F353-71FC-4F57-A745-3920E398C7AAQ33805826-B9E4263D-D0FD-4385-A784-3C8A983F0AFCQ33937396-02B2DA92-B4D6-4D8C-8A3C-5E36EA193B8CQ34071175-740795C4-6200-4E88-B790-FE1830220B2DQ34138714-9CDF81BB-4E6F-435B-B2AB-8AB5A0FD45EEQ34438371-3364A1AD-BA17-4BA8-8A95-596203813F48Q35288237-A822D949-D6F3-474A-857B-C28BBCFDD6A4Q35795350-C563B1A0-C1B1-4324-84E9-44AB80BF4D8EQ35855955-0E6B63F1-B7E6-42B4-AF58-AB98442ABA3CQ35964294-50EF85A0-FB09-492B-BA61-085A95A6A930Q36616018-711E9879-0405-42BF-9408-490506DFBDA1Q36640838-A96CF7E0-44D6-413E-946E-E1C5A79C5E63Q36754771-449F9EBF-AA4A-46E9-9ABE-2BE0CA77C73DQ37434877-18DFA4DB-19AC-4511-A7D3-08FD683A167BQ37671964-72F1CEFC-4ADD-47D8-ADAD-3D046528F786Q37691897-0D9C8C3E-9F03-4515-A4BF-BB8D13E1D77AQ38160911-E2365340-3199-44E4-9207-3416C6CEF2B6Q38259189-72916F8F-DC4A-48F0-82FC-53CBD8B07CCAQ38539607-391A32EC-DFB3-4EE9-997A-3F59A9C0DE9AQ39015929-1F98E150-4503-440B-88B0-31761AA2DCE1Q39105241-7DF35B6D-9D0B-4E1C-AC5E-7AF0EC40457EQ39112866-3E156F07-1105-4BF6-9A54-9CBF2A096F6EQ39213528-DAC117F5-25B4-42D0-A1B5-CD26A95ACA4DQ39896194-729B248F-CBD9-40E3-BAA3-95C576C0A1FDQ39902199-80890DD6-21DE-45D6-B86E-50DCCBDB75E3Q40156656-C9AA0C31-0737-4F3D-889C-A6F78B57784FQ40785709-C1B1F58F-D3A4-4073-A155-9DEB8B6266A1Q41202268-D2FD81B9-E752-4C65-9845-7D6CAF37CE5FQ43515624-7507112F-0EED-4E1D-94DE-9E1B30EB906BQ48680358-281304D6-3F45-4769-BAFC-DC0A6ED270BBQ48722726-FAD629BE-4D4D-4002-B72E-803C0E951FA8Q52839590-E16D2A3F-01D9-4C68-AE3F-7990C6EB5558Q52852837-AB6471F2-4933-48F8-AAFE-16036C8195C5Q52854775-1A858912-695B-4DE4-8D12-7E09BFA22518
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Anne E Kiltie
@ast
Anne E Kiltie
@en
Anne E Kiltie
@es
Anne E Kiltie
@nl
Anne E Kiltie
@sl
type
label
Anne E Kiltie
@ast
Anne E Kiltie
@en
Anne E Kiltie
@es
Anne E Kiltie
@nl
Anne E Kiltie
@sl
altLabel
Anne Kiltie
@en
Kiltie AE
@en
prefLabel
Anne E Kiltie
@ast
Anne E Kiltie
@en
Anne E Kiltie
@es
Anne E Kiltie
@nl
Anne E Kiltie
@sl
P106
P21
P31
P496
0000-0001-7208-2912